Clinical Trial Update: Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Xiflam™ in patients with post-acute sequelae of SARS-CoV-2 infection (Long COVID) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Xiflam™

Snippet

Sponsor: Inflammx Therapeutics Inc | Conditions: Long COVID | Phase 2 | Status: COMPLETED